Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells.

@article{Cone1999ComparisonOT,
  title={Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells.},
  author={James Cone and Shuibang Wang and N Tandon and Miranda Fong and Bing Sun and Kanako Sakurai and Masuhiro Yoshitake and Jun-ichi Kambayashi and Yongge Liu},
  journal={Journal of cardiovascular pharmacology},
  year={1999},
  volume={34 4},
  pages={497-504}
}
Cilostazol is a potent cyclic nucleotide phosphodiesterase (PDE) type 3 (PDE3) inhibitor that was recently approved by the Food and Drug Administration (FDA) for the treatment of intermittent claudication. Its efficacy is presumed to be due to its vasodilatory and platelet activation inhibitory activities. Compared with those treated with placebo, patients treated with cilostazol showed a minimal increase in cardiac adverse events. Because of its PDE3 inhibitory activity, however, the… CONTINUE READING
26 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

Similar Papers

Loading similar papers…